Appointment of Yves Decadt to the Board of Directors of Poxel

On October 31, 2025, the biopharmaceutical company Poxel announced the appointment of Yves Decadt to its Board of Directors. This decision, following a governance change in July, aims to strengthen the company's business strategy.

With over 25 years of experience in the pharmaceutical industry, Yves Decadt has held numerous senior management positions at Johnson & Johnson. He also possesses significant expertise in biopharmaceuticals and medtech. His appointment is subject to shareholder approval at the next Annual General Meeting.

To comply with the Board's gender diversity guidelines, Nicolas Trouche resigned from his position as a director. Yves Decadt, already working with Poxel, brings essential expertise to develop the company's strategic partnerships.